3-38550988-T-C
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_001099404.2(SCN5A):c.5384A>G(p.Tyr1795Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Y1795H) has been classified as Pathogenic.
Frequency
Consequence
NM_001099404.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SCN5A | NM_001099404.2 | c.5384A>G | p.Tyr1795Cys | missense_variant | 28/28 | ENST00000413689.6 | |
SCN5A | NM_000335.5 | c.5381A>G | p.Tyr1794Cys | missense_variant | 28/28 | ENST00000423572.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SCN5A | ENST00000413689.6 | c.5384A>G | p.Tyr1795Cys | missense_variant | 28/28 | 5 | NM_001099404.2 | P4 | |
SCN5A | ENST00000423572.7 | c.5381A>G | p.Tyr1794Cys | missense_variant | 28/28 | 1 | NM_000335.5 | A1 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 35
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 03, 2018 | This sequence change replaces tyrosine with cysteine at codon 1795 of the SCN5A protein (p.Tyr1795Cys). The tyrosine residue is highly conserved and there is a large physicochemical difference between tyrosine and cysteine. This variant is not present in population databases (ExAC no frequency). This variant has been reported to segregate with long QT syndrome in two families (PMID: 11410597, 18929331) and has been reported in an individual with this condition (PMID: 22129298). ClinVar contains an entry for this variant (Variation ID: 9375). Experimental studies have shown that this missense change disrupts SCN5A channel function causing a sustained inward sodium channel current and slowing the onset of inactivation with a prolongation of the action potential (PMID: 11410597, 14990510, 16254012). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 06, 2020 | Not observed in large population cohorts (Lek et al., 2016); Reported in ClinVar as pathogenic (ClinVar Variant ID# 9375; Landrum et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Functional studies have shown that Y1795C results in delayed sodium channel inactivation compared to wild type, delaying repolarization and prolonging the QT interval (Rivolta et al., 2001; Clancy et al., 2002; Tateyama et al., 2004; Berecki et al., 2006; Vecchietti et al., 2007); This variant is associated with the following publications: (PMID: 32161207, 28087622, 30361497, 30497731, 28213505, 31257342, 25460862, 24903439, 25904541, 18929331, 12417563, 16254012, 11410597, 24667783, 12084774, 16980337, 14990510, 22129298, 31865383, 19716085) - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 07, 2017 | The p.Y1795C pathogenic mutation (also known as c.5384A>G), located in coding exon 27 of the SCN5A gene, results from an A to G substitution at nucleotide position 5384. The tyrosine at codon 1795 is replaced by cysteine, an amino acid with highly dissimilar properties. This alteration has been identified in individuals with long QT syndrome type 3 (LQT3), with segregation reported in multiple families (Rivolta I et al. J. Biol. Chem., 2001 Aug;276:30623-30; Vecchietti S et al. Am. J. Physiol. Heart Circ. Physiol., 2007 Jan;292:H56-65; Benito B et al. Heart Rhythm, 2008 Oct;5:1434-40; Kapa S et al. Circulation, 2009 Nov;120:1752-60; Kilinc OU et al. Congenit Heart Dis 2012 Nov;7:E42-5). In addition, functional studies have demonstrated this alteration leads to slowed inactivation and prolonged depolarization in sodium channels (Rivolta I et al. J. Biol. Chem., 2001 Aug;276:30623-30). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Long QT syndrome 3 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 17, 2001 | - - |
Congenital long QT syndrome Other:1
not provided, no classification provided | literature only | Cardiovascular Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust | - | This variant has been reported as associated with Long QT syndrome in the following publications (PMID:11410597;PMID:15840476;PMID:19716085;PMID:19841300;PMID:18929331). This is a literature report, and does not necessarily reflect the clinical interpretation of the Imperial College / Royal Brompton Cardiovascular Genetics laboratory. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at